StockNews.com Initiates Coverage on NovaBay Pharmaceuticals (NYSE:NBY)

StockNews.com assumed coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research report report published on Friday. The firm issued a hold rating on the stock.

Separately, Ascendiant Capital Markets cut their target price on shares of NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating on the stock in a research note on Monday, November 11th.

NovaBay Pharmaceuticals Stock Performance

NovaBay Pharmaceuticals stock opened at $0.58 on Friday. The stock has a market capitalization of $2.83 million, a price-to-earnings ratio of -0.01 and a beta of 0.69. NovaBay Pharmaceuticals has a 52-week low of $0.36 and a 52-week high of $9.08. The stock’s 50 day moving average price is $0.63 and its two-hundred day moving average price is $0.97.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.